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Context and objective: BRCA1 and BRCA2 are the two principal hereditary breast cancer 
susceptibility genes, and the incidence of their mutations among breast cancer patients in Gaza 
Strip is unknown. The objective was to study the incidence of the most common BRCA1 and 
BRCA2 mutations in Gaza Strip patients with breast cancer, to establish     genetic profiles.  
Design and setting: The study is a cross sectional. The patients group size was 122 patients and 
was selected from El-Shifa Hospital and The European Hospital in Gaza Strip. The control 
sample size was 55 healthy married women. 
Methods: One hundred and seventy seven participants were interviewed face to face using a 
validated questionnaire. In addition to their demographic characteristics, ninety four participants 
were manage to genetic testing for BRCA1 and  BRCA2 mutations; Peripheral blood samples 
were collected, genomic DNA was extracted for the detection of 185delAG and 5382insC 
mutations inBRCA1, and 6174delT mutation in BRCA2, a multiplex polymerase chain reaction 
(PCR) was performed with allele-specific oligonucleotide primers. In this method, two primers 
(one specific for the mutant, and one specific for the wild-type allele) were designed. All data 
were analyzed using the Statistical Package for the Social Sciences (SPSS Inc.) version 16.0. 
Results: There were statistically significant differences among study population with respect to 
age of women (P=0.00), BMI (P=0.03), number of pregnancies (P=0.00), duration of breast 
feeding (P=0.00), using oral contraceptives (P=0.01), and relatives with cancer (P= 0.00). In 
contrast the results showed no statistically significant differences among the study population 
related to age at menarche (P=0.46), age at first birth (P=0.37), parents consanguinity (P =0.40), 
and relatives with cancer (P=1.0). Moreover, within breast cancer patients (n=122) there were 
statistically significant differences related to age of breast cancer women (P=0.04), age at first 
birth (P=0.03), and age of onset (P=0.00).  
But there were no statistically significant differences among the patients related to the  age at 
menarche (P= 0.68), number of pregnancies (P=1.0), duration of breast feeding (P=0.65), and 
using of contraceptives (P=0.25). Finally, our study results indicated that                               
BRCA1 mutation (185AG and 5382C mutations) incidence (49%) was more than BRCA2 






Conclusions: Age is associated with increasing breast cancer risk. Remarkably most risk 
increase occur during the reproductive years as breast cancer incidence is very low before 22 
years. Risk of breast cancer decreased with  an increase age at menarche, an increasing parity, a 
low age at first birth, and breast feeding. The incidence of BRCA1 mutations (185AG and 5382C 





























  .العوامل التكاثریة و الطفرات الجینیة الشائعة المتعلقة بمرض سرطان الثدي في قطاع غزة
  
  :ملخص الدراسة
 :     الھدف
  .تقییم العوامل التكاثریة و الطفرات األكثر شیوعًا المتعلقة بسرطان الثدي في قطاع غزة
  :منھجیة الدراسة
)  مریضة١٢٢(تي أصبن بسرطان الثدي عدد التقارن الدراسة بین مجموعة تجریبیة من النساء ال
سنة  من عیادة األورام بمستشفى الشفاء في غزة و المستشفى األوروبي ) ٥٠- ٢٢(تتراوح أعمارھن ما بین 
  .) ٥٥(الضابطة من النساء األصحاء عدد في خانیونس، و العینة 
عدد مرات  ورضاعة،ال والعمر عند اإلنجاب، وتشترك العینة التجریبیة و الضابطة في العمر،  
وقد تم الحصول على البیانات المستخدمة من خالل استبانھ . الحمل، ووجود أقارب مصابین بسرطان الثدي
تشتمل العمر و الوزن و العمر عند أول دورة شھریة و العمر عند الزواج و عدد الوالدات وسنة اكتشاف 
  .إلخ........ المرض 
  BRCA1 and BRCA2شائعة المسببة لسرطان الثدي وقد تم تنفیذ فحص جیني للطفرات ال  
  .  لعملیة التحلیل اإلحصائيSPSSاستخدام برنامج وقد تم . من المجموعة التجریبیة) ٩٤( عدد للمریضات
  :النتائج
 أوضحت النتائج أن ھناك فروق ذات داللة إحصائیة بین المجموعة التجریبیة و المجموعة الضابطة 
لوزن و عدد الوالدات و الرضاعة و استخدام حبوب منع الحمل و وجود أقارب من حیث العمر و دلیل ا
  .مصابین بالسرطان
على العكس من ذلك أوضحت النتائج أنھ ال توجد فروقًا ذات داللة إحصائیة بین المجموعتین من حیث العمر 
  .عند أول دورة شھریة و العمر عند أول والدة و قرابة اآلباء
ینت الدراسة وجود فروق ذات داللة إحصائیة بین أفراد المجموعة التجریبیة من و زیادة على ذلك ب  
  .حیث العمر و العمر عند أول والدة و العمر عند اكتشاف المرض
 BRCA1للجین  ) 5382Cand185AG(أخیرًا أثبتت الدراسة أن انتشار الطفرات المسببة لسرطان الثدي 
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Cancer is a common disease. All of us start with about a 1 in 3 (30%) chance of developing 
cancer (excluding skin cancer) over the course of our lives. When mutations occur in genes 
controlling cell growth and division, the cell’s normal growth-regulation breaks down, allowing it 
to progress towards malignancy. An inherited factor, or altered gene, is responsible for the pattern 
of cancer in the family [1]. Cancer has emerged beyond heart disease to become the most 
common cause of death, making the risk of contracting some type of malignancy during extended 
lifetimes more likely. Most cancers are triggered by environmental and lifestyle or unknown 
causes. Most malignancies are not due to heredity. In general, about 10% of breast cancer and 5% 
of ovarian cancer cases are contracted by carriers of defective genes [2]. 
1.1.1 Breast cancer 
1.1.1.1 Epidemiology of breast cancer  
Breast cancer (BC) is the most common malignancy in women, accounting for 31% of all female 
cancers, and responsible for 15% of cancer deaths in women [3]. One million females worldwide 
are diagnosed with BC every year. Making early detection have a high priority in medical 
management of the disease [4]. Breast cancer, one of the most common serious malignancies 
affecting women, occurs in hereditary and sporadic forms. Hereditary breast cancer accounts for 
5–10% of all cases and has some distinctive clinical features compared with sporadic breast 
cancer [5].These percentages of all breast cancer cases are associated with a strong genetic 
predisposition and highly penetrate autosomal dominant trait. Two major breast cancer 
susceptibility genes, BRCA1 and BRCA2, have been identified [6]. The cumulative lifetime risk 
for the development of the disease in the general population is estimated to be 10% [7]. It is the 
most common cancer among women in developed countries, each year more than 1.15 million 
new cases of BC are diagnosed worldwide [8]. Breast cancer is the second leading cause of 
cancer deaths in women today (after lung cancer) [9].  
1.1.1.2 The multi-step progression model of breast cancer 
Breast cancer tumorigenesis can be described as a multi-step process in which each step is 




Breast development begins in the embryonic period. In the adult breast two major cell types can 
be distinguished: the myoepithelial cell and the luminal secretory cell. Clinically and 
histopathologically, various morphologically definable steps can be identified during progression 
to malignancy [11].  
1.1.2 Genetic aspects of hereditary breast cancer 
Approximately 5% of breast cancers show a familial pattern of occurrence. This was 
related to germline mutations in different (tumor suppressor) genes of which the proteins have a 
crucial function in the breast. In patients with a germline mutation, loss of expression of the other 
allele by point mutations or deletions will lead to a significant or complete loss of protein 
function. In familial breast cancer patients, germline mutations have been described in BRCA1, 
BRCA2, PTEN, p53, ATM and CHEK2. Together, these account for most but certainly not all 
hereditary cases [12].  
1.1.2.1 Breast cancer genes BRCA1 and BRCA2 
In 1990, genetic studies provided initial evidence that the risk of breast cancer in some families is 
linked to chromosome 17q21 [13]. This 17q-associated syndrome was characterized by 
autosomal dominant inheritance with incomplete penetrance. In fact, loss of heterozygosity 
(LOH) at 17q was found in most familial breast and ovarian tumors, suggesting the involvement 
of tumor suppressor gene(s) [14, 15]. In 1994, the breast-cancer susceptibility gene, BRCA1, was 
identified by positional cloning [16].  
In 1994, a second breast cancer susceptibility gene, BRCA2, was localized by linkage analysis to 
a 6 - centimorgan interval on chromosome 13q12-13.BRCA2 accounts for a proportion of breast 
cancer roughly equal to that attributable to BRCA1. Like BRCA1, BRCA2 appears to confer a high 
risk of early-onset breast cancer in females [17]. The BRCA2 gene is composed of 27 exons 
distributed over roughly 70 kb of genomic DNA. The known sequence of 3418 amino acids 
encoded by the BRCA2 gene does not show strong homology to sequences of other proteins [18].  
In sporadic breast cancer, mutational inactivation of BRCA2 is rare as inactivation requires both 
gene copies to be mutated or totally lost [10, 19- 21]. Surprisingly, despite the inherited 
predisposition to cancer associated with BRCA1 and BRCA2, somatic disease-causing mutations 
in either of these genes are extremely rare in sporadic breast cancers [11,22]. Because only 45% 
of familial breast cancers showed evidence of linkage to BRCA1, the search for a second breast 
cancer susceptibility gene continued [23- 25].  
 
 ٣
1.1.2.2 Structure of BRCA1 and BRCA2 
Although there is no sequence similarity between the two genes, many structural and functional 
features of BRCA1 and BRCA2 are similar. Both genes have complex genomic structures (BRCA1 
is composed of 24 exons and BRCA2 of 27 exons), and they both encode large proteins (BRCA1 
1863 amino acids and BRCA2 3418 amino acids) [16, 18, 23]. BRCA1 and BRCA2 are expressed 
in a wide range of tissues and show remarkably similar temporal and spatial patterns of 
expression [26, 27].  
In BRCA1, a highly conserved zinc-binding RING finger domain is located close to the amino-
terminus (residues 20–68) [28]. Indeed, a search for interacting proteins, using the BRCA1 RING 
finger domain as bait, uncovered a further RING-domain protein designated BARD1 (BRCA1-
associated RING domain), which binds to BRCA1 [29]. They are located within the region of 
BRCA1 that is reported to activate transcription when fused to a DNA-binding domain [30, 31]. 
RING finger or BRCT domains are not present in BRCA2, nor does it bear substantial similarity 
to any other sequence presently registered in the databases. [32].  
1.1.2.3 Function of BRCA1 and BRCA2 
1.A. DNA repair 
Subsequent studies demonstrated the involvement of BRCA1 and BRCA2 in complexes that 
activate the repair of double strand breaks (DSBs) and initiate homologous recombination (HR), 
linking the maintenance of genomic integrity to tumor suppression. BRCA1 and BRCA2 co-
localize with Rad51 to form complexes [33, 34]. Eukaryotic Rad51 proteins are homologues of 
bacterial RecA and are required for recombination during mitosis and meiosis, as well as for HR 
repair of DSBs [35]. Rad51 coats single-stranded DNA to form a nucleoprotein filament [36, 37]. 
Co-localization of BRCAs with Rad51 at sites of recombination and DNA damage-induced foci 
strongly suggests that BRCAs have a role in both the detection and the repair of DSBs [36]. In 
this regard, focus formation of Rad51 is reduced after treatment with DNA-damaging agents and 
is deficient during repair of DSBs by HR in BRCA1-deficient cells [30, 38]. 
1.B. Transcriptional response to DNA damage 
BRCA1 has been implicated in the transcriptional regulation of several genes activated in 
response to DNA damage [39, 40]. A subsequent series of studies demonstrated that the C-
terminus of human BRCA1 (amino acids 1528–1863) complexes with RNA polymerase II 
through RNA helicase A [41]. This interaction appears to involve several proteins associated with 
the core polymerase complex. 
 ٤
 In fact, BRCA1 protein is a component of the RNA polymerase II holoenzyme, and deletion of 
the C-terminal 11 amino acids of BRCA1 attenuates the association with this holoenzyme [42]. 
Subsequent investigations have revealed that BRCA1 serves as a co-activator for p53 [43]. 
Available evidence suggests that the product of BRCA2 exon 3 (amino acids 23–105) activates 
transcription [44].  
1.C. DNA damage-responsive cell cycle checkpoints 
Recent studies using cells defective for different DNA damage-responsive proteins have 
demonstrated that both ATM and BRCA1 are required for effective S-phase and G2/M-phase 
checkpoints [45]. Other work has indicated that BRCA1 regulates G2/M DNA damage induced 
checkpoints through its ability to activate Chk1 kinase and thereby induce signaling cascades 
downstream of Chk1 [46]. As mentioned above, BRCA1 functions as a co-activator of p53-
mediated gene transcription. Importantly, cancer-associated mutant BRCA1 failed to activate the 
p21 promoter. BRCA1 has also been found to transactivate the cyclin-dependent kinase inhibitor 
p27KIP1 [47]. Available evidence suggested that BRCA2 mediates G2/M-phase control by 
interacting with a novel protein, BRCA2-associated factor 35 (BRAF35), which binds to 
branched DNA structures [48].   
1.1.3 Etiology of breast cancer 
The etiology of breast cancer is still poorly understood. Several known risk factors can only 
explain a small proportion of breast cancer cases [49]. This is most strongly seen in families with 
a germline mutation in a breast cancer susceptibility gene such as BRCA1 and BRCA2 [50,51]. 
However, because of their low allele frequencies in the general population, it is believed that only 
5 to 10% of all breast cancers are associated with the presence a specific germline mutation. 
Besides the above mentioned well known genetic alterations, epigenetic alterations are among the 
most common molecular alterations in human neoplasia [52-54].  
1.1.3.1 Factors increase or decrease the chance of developing breast cancer 
The following factors have been associated with increased or decreased risk of developing breast 
in the general population. It is not yet known exactly how these factors influence risk in people 
with BRCA1 or BRCA2 mutations. In addition, a significant portion of hereditary breast cancers 
are not associated with BRCA1 or BRCA2 mutations [55]. 
Age and gender [56], Family history [56], Genes [56], Pregnancies, and breast feeding [56, 




Physical activity [58], Birth control pills (Oral contraceptives) [58-60], Hormone 
replacement therapy (HRT) [61- 63], Obesity [57,64], and Dietary fat [65]. 
1.2 Significance 
As many as 5%–10% of diagnosed women carried an inherited mutation in the hereditary breast 
and ovarian cancer genes, BRCA1 and BRCA2. The presence of these mutations confers elevated 
risks of several adverse health outcomes. The general female population has a lifetime risk of 
breast cancer but women with BRCA1/2 mutations face much higher risks of this malignancy. 
Carriers of these mutations have a lifetime risk, and the diagnosis is often made at a younger age 
(i.e., before menopause). Secondly, women in the general population with breast cancer have an 
estimated 20-year cumulative risk of developing a contralateral breast cancer. In contrast, 
BRCA1/2 carriers have a lifetime risk of up to 65% of developing a contralateral breast 
cancer[47]. 
It is the first study in Gaza  Strip about cancer and specialized in breast cancer. The study of 
correlation between the different risk factors of breast cancer mutations in BRCA1 and BRCA2 
will give indication about future incidence of the disease. As the breast cancer is the most 
common type of female malignancies ( 39% ) in Gaza Strip. 
1.3 Objectives 
The general objective of the study is to investigate the incidence of BRCA1 and BRCA2 
mutations in Gaza familial and sporadic cases of breast cancer in an attempt to establish a genetic 
profile for this population. This information will facilitate BRCA1 and BRCA2 mutational 
screening in the Gaza Strip population and identify individuals at high risk, who will then be able 
to seek genetic counseling.   
The specific objectives were 
1. To assess the incidence of breast cancer in Gaza Strip. 
2. To estimate the incidence of the most common BRCA1, BRCA2 mutations (185delAG 
and 5382insC of  BRCA1, and 6174delT of BRCA2 ) in breast cancer patients in Gaza 
Strip. 
3. To investigate the effect of reproductive risk factors associated with breast cancer of 






2.1 Breast cancer gremline mutations 
Breast Cancer is a disease in which the uncontrollable growth and division of malignant cells in 
the tissue of the breast lead to the formation of a “lump”. These cells can invade the healthy 
surrounding tissues through the lymph or blood vessels and result in the formation of secondary 
metastases. [66] 
Breast carcinoma is the most common malignancy among females worldwide, and more 
than 1,000,000 new cases are diagnosed every year. Breast cancer (BC) may be of early or late 
onset, depending on age of onset. However, the cutoff value ranging from 35 to 50 years for early 
onset BC varies among investigators [67]. Breast cancer is the most prevalent malignancy and 
primary cause of cancer death in women worldwide. It accounts for 23% of all cancers among 
women, and is the second most common cancer overall when both sexes are considered together 
[68]. 
To date, two major genes, BRCA1 and BRCA2, germline mutations of which predispose to 
both breast and ovarian carcinoma, have been identified. More than 1000 distinct germline 
alterations have been identified in each gene, most of them appearing uniquely in a single family 
[the Breast Cancer Information Core (BIC) Database]. [16, 24]. 
 
2.2 Types of breast cancer 
Breast cancer is a cancer that propagates in different tissues of the breast. Based on type of tissue 
breast cancer is divided into: 
1. Ductal carcinoma,  
2. Lobular carcinoma. 
Breast cancer may be invasive or noninvasive. Invasive means it has spread to other tissues. 
Noninvasive means it has not yet spread. Noninvasive breast cancer is referred to as "in situ." 
1. Ductal carcinoma in situ (DCIS), or intraductal carcinoma 




2.3 Symptoms of breast cancer 
Symptoms of advanced breast cancer may include bone pain, breast pain or discomfort, skin 
ulcers, swelling of one arm (next to breast with cancer), weight loss. 
 
2.4 Breast cancer treatment 
In general, cancer treatments may include: 
 Chemotherapy to kill cancer cells  
 Radiation therapy to destroy cancerous tissue  
 Surgery to remove cancerous tissue [56]. 
 
2.5 Breast cancer incidence 
The incidence of breast cancer in Arab women is low compared to the incidence in the Jewish 
population in Israel; still, it is the most common malignancy among Arab women. There is a 
steep rise in breast cancer incidence in the Arab population in Israel over the last 10 years that 
can be attributed to life style changes. But, the younger age of BC onset in Arab women 
compared with that of the Jewish population is suggestive of a genetic component in BC 
occurrence in that population. The family history of 31 women of Palestinian Arab (PA) origin 
affected with breast (n=28), ovarian (n=3) cancer was studied. Using denaturing high 
performance liquid chromatography (DHPLC) to screen for mutations of BRCA1/2 in 4 women 
with a personal and family history highly suggestive of genetic predisposition. A novel BRCA1 
mutation, E1373X in exon 12, was found in a patient affected with ovarian cancer. They found a 
novel BRCA1 mutation in a family of PA origin with a history highly compatible with BRCA1 
phenotype. This mutation was not found in additional 30 PA women affected with BC or ovarian 
cancer. However, it is likely that the E1373X mutation is not a founder frequent mutation in the 
PA population [69]. 
Relatives of breast cancer cases have an increased risk of the disease. The risk increases with 
increasing numbers and decreasing age of onset of affected relatives. In families with a BRCA1 or 
a BRCA2 mutation, individual carrier status predicts the risk of breast cancer. In relatives of cases 
where both BRCA1 and BRCA2 mutations are excluded, the risk remains undetermined. 
Standardized incidence ratios (SIRs) and cumulative cancer incidences were calculated for 
relatives of a population based set of early-onset breast cancer index cases (younger than age 41 
years) with a defined BRCA mutation status (n=203). 
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 In first-degree relatives (FDRs) of mutation-negative cases, breast cancer incidences (SIR=2.3) 
were increased. In high-risk individuals with at least one relative with breast cancer apart from 
the index case, but no BRCA mutation in the family, breast cancer incidence was increased 
(SIR=5.3). The cumulative incidence of breast cancer at ages 50 and 70 years for FDRs of index 
cases without a BRCA mutation was 3.6% and 12.8%, respectively. Similarly, the cumulative 
incidence of breast cancer for high-risk women was 6.3% and 21.1% at ages 50 and 70 years, and 
that for FDRs of BRCA mutation carriers was 17.2% and 27.7% at the same ages. So that the 
incidence of breast cancer was increased for FDRs of women (with early-onset breast cancer 
irrespective of the BRCA) status in the family. Risk increases with decreasing age and with 
increasing number of affected relatives [70]. 
There has been contradictory evidence as to whether BRCA1 associated breast cancers have a 
poorer prognosis than non-BRCA1 cancers. In an issue of breast cancer researcher Robson and 
colleagues provide further evidence for poorer survival in BRCA1 carriers and show that it could 
be attributed to failure to treat small node-negative grade 3 breast cancers with chemotherapy. 
There still remains little evidence for a survival difference for BRCA2 related breast cancers. 
Although the high contralateral breast cancer risk is confirmed by this study there is no real 
evidence for an increase in recurrence or new primary breast cancers in mutation carriers up to 
the 10-year point[71]. 
 
2.6 Mutations in BRCA gene 
Linkage analyses of more than 200 families have demonstrated BRCA1 to be involved in 80–
90% of the hereditary breast-ovarian cancer families and in 40– 45% of the site-specific breast 
cancer families [72]. The percentage of breast cancer-only families attributed to BRCA1 
mutations rises to almost 70% if the median age of onset of breast cancer in families is less than 
45 years [73]. Epigenetic changes differ from genetic changes mainly in that they occur at a 
higher frequency than genetic changes, are reversible upon treatment with pharmacological 
agents and occur at defined regions in a gene [53]. Breast cancer in males is sometimes hereditary 
but does not seem to be a feature of BRCA1 families [74]. In a recent genetic analysis study 
using a sample of hereditary breast cancers from Northern American women, the pattern of 
hereditary cancer in 14 (61%) of the 23 families studied was attributed to BRCA1 by a 
combination of linkage and mutation analyses [75]. In the Polish population, the most important 
mutation was a very high frequency of single BRCA1 5382insC mutation. 
 ٩
 Mutations 185delAG and C61G were less frequent. A recurrent mutation was earlier described 
also in the BRCA2 gene–9631delC [76]. 
A study was conducted to delineate the genetic component of BC/ OC among the PA 
population [77]. Only full sequencing of the BRCA1/2 genes and study of the particular BRCA1 
mutation that they identified in a larger population may provide complete picture regarding the 
role of BRCA1/2 mutations in the studied population. Based on their study full BRCA1/2 
screening should be offered to families with a history highly suggestive of genetic predisposition. 
It is likely that the E1373X mutation is not a founder frequent mutation in the PA population. 
BRCA1 could probably explain the majority of hereditary breast cancer that exists in the 
North American population, but one or more additional genes may yet be found that explain 
some proportion of the rest. Germline mutations in BRCA1 were initially detected in five of eight 
families that demonstrated linkage to BRCA1 and in four of 44 breast and ovarian tumors [78, 
79]. To date, at least 100 unique mutations have been identified by an international collaboration 
[80]. Sixty-three mutations, 38 of which were distinct, have been identified through a complete 
screen of the BRCA1 gene. About 85% of all alterations are frame shift or nonsense mutations 
and lead to a truncated protein product. They are spread throughout all of the coding sequence, 
leading to considerable heterogeneity in the size of the putative truncated mutant product. The 
biochemical consequence of these truncations is not known. The remaining15%of the mutations 
are either missense alterations which affect the cysteine residues within the RING domain or 
inferred regulatory mutations that lead to the absence of a stable transcript from the mutant allele 
[81, 82]. Although there is no clustering of mutations, identical mutations have been found in 
several unrelated individuals. Three of them appear very common: 5382insC in codon 1756, 
185delAG in codon 23, and 4184del4 in codon 1355 [82].Not all BRCA1 mutations are 
alterations in the coding sequence, since there are a number of families strongly linked to BRCA1 
for which no mutations in coding sequences have been detected [81]. BRCA1 or BRCA2 germline 
mutations increase the risk of developing breast cancer. Tumors cells from germline mutation 
carriers have frequently lost the wild-type allele. This is predicted to result in genomic instability 
where cell survival depends upon dysfunctional checkpoint mechanisms. Tumorigenic potential 
could then be acquired through further genomic alterations. Surprisingly, somatic BRCA 
mutations are not found in sporadic breast tumors. BRCA1 methylation has been shown to occur 
in sporadic breast tumors and to be associated with reduced gene expression [82]. The mutational 
spectrum of the BRCA1 gene has not yet been completely characterized and frequency of the 
mutations may have different geographic and ethnic distributions. Overall, women of Eastern 
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European decent have slightly raised relative risk of breast cancer. In contrast, the cumulative 
incidence of breast cancer in Japan is low. This phenomenon has been mainly explained by 
environmental factors. However, it has also been suggested that genetic factors, which may vary 
between races, might be involved in this difference. Within hereditary breast cancer families, 
affected and unaffected individuals will harbour similar perspectives; consequently, disagreement 
with regard to the most suitable application of genetic testing information may not present an 
additional source of stress and confusion in the health-related decision making of individual 
family members. However, the large standard deviations for preference scores indicate that this 
may not hold for a substantial number of families in the population from which this sample was 
selected. Findings from this study did not support the hypothesis that women indicating they 
would like to undergo BRCA1/BRCA2 testing in the near future would display greater preferences 
for the genetic testing-related health states than women who either did not want the test or who 
were uncertain. The question thus arises as to the applicability of utility assessment for use in 
clinical decision making. This non significant finding suggests, for example, that women who 
view the notion of prophylactic mastectomy and oophorectomy as extremely undesirable and 
perhaps not even a viable option are no less likely to want to know their BRCA status than 
women who would be more prepared to undertake such preventive measures [12].  
Deciding among treatment options requires patients and their physicians to evaluate 
numerous disease- and patient-related factors, not least of which are the anticipated ways in 
which certain therapeutic outcomes may affect the physical, psychological, and social functioning 
of the patient. The decision-making process has been complicated further by the cloning of 
BRCA1 and BRCA2, specific genes associated with hereditary breast cancer [16, 18, 23, 83]. 
With the implementation of BRCA genetic testing, women are now faced with several new 
possibilities and outcomes to consider in the management of their current and future health, 
including prophylactic mastectomy and/or oophorectomy and participation in preventive drug 
trials. Specifically, older participants assigned lower utilities to dialysis and kidney 
transplantation but higher utilities to health states requiring hospitalization. In the context of 
breast cancer, a decision analysis of prophylactic mastectomy and oophorectomy in BRCA-
positive women revealed that participants’ preferences differed by age, sex, occupation, and self-
perceived health status [84]. 
Several anthropometric measures have been found to be associated with the risk of breast 
cancer. Current weight, body mass index, and adult weight gain appear to be predictors of 
postmenopausal breast cancer.  
 ١١
These factors have been associated with a reduced risk of premenopausal breast cancer. 
They asked whether there is an association between changes in body weight and the risk of breast 
cancer in women who carry a mutation in either breast cancer susceptibility gene, BRCA1 or 
BRCA2. A matched case–control study was conducted in 1,073 pairs of women carrying a 
deleterious mutation in either BRCA1 (n = 797 pairs) or BRCA2 (n = 276 pairs). Women 
diagnosed with breast cancer were matched to control subjects by year of birth, mutation, country 
of residence, and history of ovarian cancer. Information about weight was derived from a 
questionnaire routinely administered to women who were carriers of a mutation in either gene. 
Conditional logistic regression was used to estimate the association between weight gain or loss 
and the risk of breast cancer, stratified by age at diagnosis or menopausal status. A loss of at least 
10 pounds in the period from age 18 to 30 years was associated with a decreased risk of breast 
cancer between age 30 and 49 (odds ratio (OR) = 0.47; 95% confidence interval (CI) 0.28–0.79); 
weight gain during the same interval did not influence the overall risk. Among the subgroup of 
BRCA1 mutation carriers who had at least two children, weight gain of more than 10 pounds 
between age 18 and 30 was associated with an increased risk of breast cancer diagnosed between 
age 30 and 40 (OR = 1.44, 95% CI 1.01– 2.04). Change in body weight later in life (at age 30 to 
40) did not influence the risk of either premenopausal or postmenopausal breast cancer.  The 
results suggested that weight loss in early adult life (age 18 to 30) protects against early-onset 
BRCA-associated breast cancers. Weight gain should also be avoided, particularly among BRCA1 
mutation carriers who elect to have at least two pregnancies [85].   
The relationship between health state utilities and age, sex and social class has been 
examined; only age emerged as a significant predictor of patient preferences [86].  
 
2.7 Risk factors of breast cancer 
2.7.1 Age-dependent penetrance mutations in the BRCA1 gene 
Age is associated with increasing breast cancer risk. However, remarkably, most risk increase 
occurs during the reproductive years as breast cancer incidence is very low before age 25, and 
increases up to 100 fold by age 45 [86]. 
Various genotype–phenotype correlation attempts have yielded important data pertaining 
to the consequences of BRCA1 mutations. However, little is known about the effects of recurrent 
BRCA mutations on expressivity and the age of onset of cancer in a population. It was addressed 
whether different exon mutations have variable expressivity especially in relation to the age of 
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onset of breast cancer. It was shown that different BRCA1 gene mutations have distinct effects 
that influence the age of onset of breast or ovarian cancer. Mutations in exon 2 of the BRCA1 
gene had significantly lower penetrance compared with mutations of exons 11, 13 and 20. The 
median age of affliction with breast cancer was 55 years for 185delAG in exon 2 (95% 
confidence interval (CI) 46.7 to 59.5), 47 years for the 4184delTCAA mutation in exon 11 (95% 
CI 39 to 55.4), and 41 years for exon 13 duplication (95% CI 32.9 to 49.7) of the BRCA1 gene. 
Moreover, 14 novel mutations in BRCA1 and BRCA2 genes in the Yorkshire/Humberside 
population were identified. The conclusion of the study was that 185delAG mutation of the 
BRCA1 gene is a low penetrance mutation that is age dependent especially when compared with 
the exon 13 duplication mutations [87].  
They found age and education level to be negatively correlated with and independently 
predictive of, patients’ utilities for colonoscopy with perforation [88].  
They examined the relationship between health state utilities and age, sex and social class; only 
age emerged as a significant predictor of patient preferences [89]. 
Median age at presentation was 45 years. A total of 288 (33.2%) patients were aged ≤ 40 
years. Hormone receptors were positive in 69% of patients 40 and 78.2% of patients above 40       
(p= 0.00). Younger patients had a greater probability of recurrence at all time periods (p= 0.03). 
Adjuvant chemotherapy was administered to 87.9% of younger and 65.6% of older patients           
(p< 0.00). No significant difference in radiation therapy between the two groups. The young age     
(≤ 40) is an independent risk factor for relapse in operable Saudi breast cancer patients [90]. 
2.7.2 Pregnancies and breast feeding 
Multiparity, young age at first childbirth and breast-feeding are associated with a reduced risk of 
breast cancer in the general population. The breast cancer predisposition gene, BRCA1, regulates 
normal cell differentiation.. There was no statistically significant difference in the risk of breast 
cancer between porous and nulliporous women. Among porous women, an increasing number of 
full-term pregnancies was associated with a statistically significant decrease in the risk of breast 
cancer (P trend = 0.008); risk was reduced by 14% (95% confidence interval [CI] = 6% to 22%) 
for each additional birth. This association was the same for carriers of mutations in either BRCA1 
or BRCA2 and was restricted to women older than 40 years. In BRCA2 mutation carriers, first 
childbirth at later ages was associated with an increased risk of breast cancer compared with first 
childbirth before age 20 years (20 – 24 years), hazard ratio [HR] = 2.33 [95% CI = 0.93 to 5.83]; 
25 – 29 years, HR = 2.68 [95% CI = 1.02 to 7.07]; ≥ 30 years, HR = 1.97 [95% CI = 0.67 to 
5.81]), whereas in BRCA1 mutation carriers, first childbirth at age 30 years or later was 
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associated with a reduced risk of breast cancer compared with first childbirth before age 20 years 
(HR = 0.58 [95% CI = 0.36 to 0.94]). Neither history of interrupted pregnancies (induced 
abortions or miscarriage) nor was history of breast-feeding statistically significantly associated 
with the risk of breast cancer. So BRCA1 and BRCA2 mutation carriers older than 40 years show 
a similar reduction in breast cancer risk with increasing parity as non-carriers [91]. A negative 
association between risk and duration of breast feeding was observed only in the mutation 
carriers. These associations were not statistically significant, but the effects of the two variables 
differed significantly according to mutation status (P=0.007 and P=0.045 for interaction with 
number of births and with duration of breast feeding, respectively). That was maintained when 
limiting the analysis to women diagnosed older than the age of 40 years. They concluded that the 
association between breast cancer and the number of pregnancies and between breast cancer and 
the duration of breast feeding was not the same for carriers and non carriers of a detrimental 
BRCA2 mutation. In the context of other epidemiological and laboratory studies, this may 
indicate that the product of the BRCA2 gene has a function relating to the differentiation of 
epithelial tissue in the breast. An increasing age at menarche, a low age at first birth, an 
increasing parity and breast feeding are associated with a reduced risk of breast cancer in the 
general population [92 – 95]. 
 
2.7.3 Hormonal and oral contraceptives influence breast cancer 
The author and the colleagues (Hulka BS and Moorman PG. 2001) suggested that the 
involvement of reproductive hormones in breast cancer etiology. Other known risk factors 
involved life style factors, environmental factors, a history of benign proliferated breast lesions, 
and genetic factors. Reproductive factors such as nulliparity, early menarche and older age at first 
have pregnancy been associated with an increased breast cancer risk [86, 96].  
In addition, exogenous hormonal influences like using oral contraceptives may increase 
breast cancer risk. However, the opposite was demonstrated in many epidemiologic studies in 
which no association between the use of oral contraceptive and the risk of breast cancer was 
shown. Recently, however, a large meta-analysis calculated a small but significant increase in 
relative risk of breast cancer (RR = 1.24) in current oral contraceptive users [97].  
The use of hormone replacement therapy (HRT) by postmenopausal women was also shown to 
be associated with enhanced breast cancer risks, predominantly affecting the chance of 
development of a hormone receptor-positive breast cancer [98].  
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Other factors associated with breast cancer included dietary factors such as high fat intake, low 
vegetables/fruit and low fiber intake may also increase risk [99]. Furthermore, alcohol 
consumption was significantly associated with a higher risk of breast cancer [100, 101]. Some 
studies related socio-economic status to breast cancer risk, but these findings can probably be 
explained by differential life styles such as alcohol, diet and reproductive patterns [102].  
 
2.7.4 Familial history and hereditary breast cancer 
BRCA1 or BRCA2 have been estimated to include approximately 45% breast cancer susceptibility 
syndromes that are transmitted as a dominant autonomic trait, accounting for about 40% cases of 
families with both early onset breast cancers [103]. 
BRCA1 and BRCA2 account for most cases of hereditary breast cancer in the United 
States and Europe. These are suppressor genes that are inherited in an autonomic dominant 
fashion. Several studies showed that the histological and molecular phenotype of BRCA-
associated tumors is different from that of nonhereditary tumors. There is a difference in steroid 
receptor status between BRCA1 and 2 tumors regard to chemoprevention of breast cancer with 
anti estrogens. 93-100% of BRCA2 associated breast cancers are ER/PR+. Breast cancers 
associated with BRCA1 mutations are frequently of a higher grade and are hormone receptor-
negative in one third of them. A higher proportion of cancers related to a BRCA1 mutation have 
atypical or typical modularly histological features. The lifetime cumulative risk of invasive breast 
cancer for individuals with BRCA1 or BRCA2 mutations ranges from 50% to 87%. Ongoing 
clinical trials will determine who the optimal subjects are for screening, how screening and 
counseling should be conducted and what type of societal involvement is needed so that genetic 
screening can be used without exposing the subject to unexpected risks and consequences [104]. 
Only 5–10% of newly diagnosed BC patients and about 5% of OC cases are attributable 
to high penetrate breast cancer predisposing genes. BRCA1 and BRCA2 can be identified in about 
half of the breast cancer patients with positive family history [105]. 
 There has been a significant increase in breast cancer incidence in Palestine. Young age 
onset and cancer family history are suggestive of genetic predisposition. Molecular screening for 
BRCA1 and BRCA2 mutation is an established component of risk evaluation and management of 
familial breast cancer. Carriers of germ line mutations in these  two genes are known to be at high 
risk of breast cancer. They had studied the family history of 300 Palestinian women affected with 
breast cancer. They had identified those families with cancer history and utilized direct 
sequencing to screen for mutation in BRCA1 and BRCA2. 
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 A novel BRCA2 mutation, E2229X in exon 11 was found in 3 unrelated patients. No carriers for 
the mutation were detected among 296 probands with breast cancer. The mutation did not appear 
among 1000 healthy Palestinian controls. The full BRCA1/2 screening should be offered to 
patients with characteristic family history [106].   
Both the maternal and paternal family history should be detailed even if the history of 
cancer or familial gene mutation is known to be on one side of the family. A thorough family 
history may uncover other cancer syndromes or hereditary conditions [107]. 
The inheritance of genetic disorders in the PA population. The Arab population is 
genetically heterogeneous; therefore the distribution of genetic disorders in this population is not 
uniform. Most of the PA population in Israel and in the Palestinian Authority lives in villages/ 
tribes that were founded by few individuals less than 10 generations ago and often includes less 
than 10,000 inhabitants. Consanguineous marriages are frequent in this population, therefore, 
each of the villages may be considered as a small isolated community [108]. Diseases that are 
relatively frequent among Muslim Arabs are more homogenously prevalent in the PA population 
in Israel as well [109]. 
 
2.7.5 Body weight, height and the risk of breast cancer 
Several anthropometric measures have been found to be associated with the risk of breast cancer. 
Current weight, body mass index, and adult weight gain appear to be predictors of 
postmenopausal breast cancer. These factors have been associated with a reduced risk of 
premenopausal breast cancer. They asked whether there is an association between changes in 
body weight and the risk of breast cancer in women who carry a mutation in either breast cancer 
susceptibility gene, BRCA1 or BRCA2. A matched case–control study was conducted in 1,073 
pairs of women carrying a deleterious mutation in either BRCA1 (n = 797 pairs) or BRCA2 (n = 
276 pairs). Women diagnosed with breast cancer were matched to control subjects by year of 
birth, mutation, country of residence, and history of ovarian cancer. Information about weight 
was derived from a questionnaire routinely administered to women who were carriers of a 
mutation in either gene. Conditional logistic regression was used to estimate the association 
between weight gain or loss and the risk of breast cancer, stratified by age at diagnosis or 
menopausal status. A loss of at least 10 pounds in the period from age 18 to 30 years was 
associated with a decreased risk of breast cancer between age 30 and 49 (odds ratio (OR) = 0.47; 
95% confidence interval (CI) 0.28–0.79); weight gain during the same interval did not influence 
the overall risk. Among the subgroup of BRCA1 mutation carriers who had at least two children, 
 ١٦
weight gain of more than 10 pounds between age 18 and 30 was associated with an increased risk 
of breast cancer diagnosed between age 30 and 40 (OR = 1.44, 95% CI 1.01– 2.04). Change in 
body weight later in life (at age 30 to 40) did not influence the risk of either premenopausal or 
postmenopausal breast cancer. The results suggested that weight loss in early adult life                    
(age 18 to 30) protects against early-onset BRCA-associated breast cancers. Weight gain should 
also be avoided, particularly among BRCA1 mutation carriers who elect to have at least two 
pregnancies [85]. 
 
2.8 Genetic testing 
Genetic testing enables women at risk for hereditary breast and/or ovarian cancer to find out 
whether they have inherited the gene mutation (BRCA1/BRCA2), and if so, to option  for frequent 
surveillance and/or prophylactic surgery (bilateral mastectomy and / or oophorectomy). Here, a 
follow-up is described for 63 healthy women at 50% risk of being a BRCA1/BRCA2 mutation 
carrier who underwent genetic testing. The course of distress and problems regarding body image 
and sexuality up to 1 year after disclosure of the test-outcome were described separately for 
mutation carriers undergoing mastectomy (n=14), for mutation carriers opting for surveillance 
(n=12) and for non-mutation carriers (n=37). Women opting for prophylactic mastectomy had 
significantly higher distress levels than mutation carriers who opted for surveillance, and the non-
mutation carriers. This difference in levels of distress was highest at pre- and post-test and had 
almost disappeared at 1-year follow-up. Besides, mutation carriers opting for prophylactic 
mastectomy were more often in their thirties, more often had young children and had a longer 
awareness of the genetic nature of cancer in the family than those opting for regular surveillance. 
Adverse effects were observed in women who underwent prophylactic mastectomy (mostly in 
combination with immediate breast reconstruction) regarding the perception of how their breast 
region looked like and felt, the intimate relationship and physical wellbeing whereas women 
opting for prophylactic mastectomy reported more distress than the other women in the study, 
their distress levels had significantly decreased 6 months or longer after surgery, possibly due to 
the significant risk reduction of developing breast cancer. This might explain why most women 
who underwent prophylactic mastectomy were satisfied with this decision, despite a perceived 
negative impact on body image, the intimate relationship and physical wellbeing [110]. 
One of the major benefits of genetic testing is the possibility of a more individually 
tailored application of risk management strategies in women from at-risk families. Options of  
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intensive surveillance or radical prophylactic surgical interventions (bilateral mastectomy and/or 
oophorectomy) may be discussed with BRCA1/BRCA2 gene mutation carriers, whereas 
surveillance can be discontinued in most non-mutation carriers (those who are older than 50 years 
and/or have relatives with breast cancer on the other side of the family may continue some form 
of breast surveillance). Reported proportions of BRCA1/BRCA2 gene mutation carriers 
expressing interest in prophylactic mastectomy or oophorectomy are highly variable [82, 111].  
The process of genetic testing is often deemed a family affair. Several studies have 
indicated that individuals undergo BRCA1/2 testing not only to learn about their own cancer risks 
and options for screening and prevention, but also to gather information for potentially at-risk 
relatives. However, many individuals are not prepared for the medical and emotional implications 
that accompany the genetic testing process. While genetic providers have an obligation to inform 
individuals of the implications of BRCA1/2 test results for at-risk relatives, they must also strive 
to respect and maintain autonomy and confidentiality. In addition, methods of post-test support 
and follow-up to facilitate the disclosure process for patients and their family members as well as 
foster positive communication will be discussed [112].  
 
2.8.1 Genetic counseling 
Genetic counseling is the process of helping people understand and adapt to the medical and 
familial implications of genetic contributions to disease. This process integrates the interpretation 
of family and medical histories to assess the chance of disease occurrence and recurrence, 
education about inheritance, testing, management, prevention, resources and research, and 
counseling to promote informed choices and adaptation to the risk or condition. Information is 
provided in a non-directive manner, allowing patients to make decisions regarding genetic testing 
compatible with their personal beliefs, experiences, religious conviction and financial status. 
However, even in the setting of non-directive counseling, heightened cancer screening and 
prevention measures may sometimes be presented as recommendations [113]. 
During the genetic counseling process, women considering genetic testing must be 
thoroughly informed about the potential drawbacks in the event of a positive test result. For 
instance, the options available to them to prevent the onset of cancer are quite limited at this time, 
and those that are available bring no guarantees of future cancer avoidance. A clear 
understanding of these potential shortcomings of BRCA testing will ensure that the complete and 
accurate ‘cost benefit analysis’ required for informed consent is achieved. As advances in 
treatment for cancer continue to extend survival of patients, the quality of life following treatment 
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has become a topic of considerable focus. It is now well accepted that in establishing decision 
models for medical interventions, it is not sufficient to look only at improvements in life 
expectancy; there must also be an incorporation of the health-related quality of life afforded to 
patients by a particular treatment [12]. 
 
2.8.2 Mutation testing during adjuvant radiotherapy 
The study assessed psychological distress during the first year after diagnosis in breast cancer 
patients approached for genetic counseling at the start of adjuvant radiotherapy and identified 
those vulnerable to long-term high distress. There were no differences between the subgroups of 
approached patients. Predictors for long-term high distress or an increase in distress over time 
were pre-existing high distress and a low quality of life, having children, and having no family 
members with breast cancer. It was concluded that breast cancer patients can be systematically 
screened and approached for genetic counseling during adjuvant radiotherapy without imposing 
extra psychological burden. Patients vulnerable to long term high distress already displayed high 
distress shortly after diagnosis with no influence of their medical treatment on their level of 
distress at long-term [114].  
 
2.9 Prevalence of BRCA1 and BRCA2 Mutations 
A complete list of the seven founder mutations can be found in Table 2.1. These mutations are so 
common that often individuals of French Canadian ancestry initiate testing of the BRCA genes 
with a panel of the founder mutations and if negative then consider reflex to complete evaluation 


































About 60% of Jews are Ashkenazi (Eastern European) and others are Sephardi (Middle Eastern/ 
African and Iraqi) or of mixed ancestry. Other major populations include Muslim Arabs, 
Christian Arabs, Druze, and Bedouin. Three Ashkenazi Jewish founder mutations in BRCA1 
(185delAG and 5382insC) and BRCA2 (6174delT) genes have combined frequency of 2.5% in 
general Ashkenazi population and appear in f10% [116, 117] of breast cancer cases in Ashkenazi 
Jewish women. In Ashkenazi Jewish breast cancer patients with family history of breast and 
ovary cancer, 45% carry a mutation in one of these genes [117]. The mutations in other breast 
cancer susceptibility genes (PTEN, ATM, and p53) are not frequent enough in Israel to explain 
the rest of BRCA-negative familial breast cancers [117, 118].  
 
 
POPULATION BRCA1 BRCA2 
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185delAG 
5382 ins C 
6174delT 
Icelandic  999del15 
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del exon 13 
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Sixty breast cancer Egyptian patients, derived from 60 families, were selected for 
molecular genetic testing of BRCA1 and BRCA2 genes. The study also included 120 healthy first 
degree female relatives of the patients, either sisters and/or daughters, for early detection of 
presymptomatic breast cancer mutation carriers. the studied exons. Mutations in both BRCA1 and 
BRCA2 genes were detected in 86.7% of the families. The study indicated that 60% of these 
families were attributable to BRCA1 mutations, while 26.7% of them were attributable to BRCA2 
mutations. Four mutations were detected in the BRCA1 gene, while one mutation was detected in 
the BRCA2 gene. Asymptomatic relatives, 80(67%) out of total 120, were mutation carriers. The 
results showed that BRCA1 and BRCA2 genes mutations are responsible for a significant 
proportion of breast cancer. BRCA mutations were found in individuals with and without family 
history [119].                                              The frequency of BRCA1 (185delAG) mutation in 
Egyptian female patients with breast cancer was estimated. Forty selected female patients with 
breast cancer, 80 of their female relatives and 10 healthy females as a control group were 
included. The age of onset of breast cancer was below 40 years in 25 (62.5%) patients and above 
40 years in 15 (37.5%) patients. There were significant differences among the patients regarding 
the age at menarche before 13 years (p=0.011), onset of breast cancer (p<0.001), parity 
(p<0.001), first delivery before 30 years of age (p=0.04), breast feeding (p=0.002), and positive 
family history (p<0.001). The frequency of BRCA1 (185delAG) mutation was 10% in the 
patients. Eight percent of patients with early onset below 40 years and 13.5% of patients with 
onset after 40 years were heterozygotes for the mutation [120]. The incidence of breast cancer in 
Korea has been increasing in recent years, such that it is now the most common female cancer. 
Breast cancer in Korea is characterized by an earlier age of onset than in Western countries, 
suggesting that it would be related with genetic background. They assayed germline mutations in 
the BRCA genes to evaluate their genetic pathology in Korean breast cancer patients. The study 
subjects consisted of 173 patients at clinically higher risk and 109 unselected patients. Germline 
mutations in the entire coding sequences of the BRCA1 and BRCA2 genes were analyzed by 
Conformation-Sensitive Gel Electrophoresis (CSGE), and any aberrantly-sized band was 
sequenced. BRCA mutations were present in 12.7% of the high risk patients, compared with 2.8% 
of the unselected patients. Among high risk patients, mutations were most prevalent in patients 
with a family history of breast or first-degree ovarian cancer (22.1%), followed by those with 
male breast cancer (20%), bilateral breast cancer (20%), multiple organ cancer including breast 
(13%) and younger breast cancer patients (aged <35 yr)(8.1%). Moreover, BRCA mutations were  
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detected in 34.8% of patients having two high risk factors. These findings suggest that BRCA 
gene mutation analysis should be performed on Korean patients with high-risk factors for breast 
cancer [121]. Breast cancer rates and median age of onset differ between Western Europe and 
North Africa. In Western populations, 5 to 10 % of breast cancer cases can be attributed to major 
genetic factors such as BRCA1 and BRCA2, while this attribution is not yet well defined among 
Africans. To help determine the contribution of BRCA1 mutations to breast cancer in a North 
African population, they analyzed genomic DNA from breast cancer cases ascertained in Algiers. 
Both familial cases (at least three breast cancers in the same familial branch, or two with one 
bilateral or diagnosed before age 40) and sporadic cases less than 38 years of age were studied. 
Complete sequencing plus quantitative analysis of the BRCA1 gene was performed. Early-onset 
sporadic was 9.8 % (5/51) and 36.4 % (4/11) of familial cases were found to be associated with 
BRCA1 mutations. One mutation, c.798_799delTT, was observed in two Algerian families and in 
two families from Tunisia, suggesting a North African founder allele. Algerian non-BRCA1 
tumors were of significantly higher grade than French non-BRCA tumors, and the age at 
diagnosis for Algerian familial cases was much younger than that for French non-BRCA familial 
cases. In conclusion, the observation was that the frequency of BRCA1 mutations among young 
breast cancer patients was higher than observed in Europe, suggesting biological differences and 
that the inclusion criteria for analysis in Western Europe may not be applicable for the Northern 
African population. Studies of breast cancer in the Maghreb (including Morocco, Algeria, 
Tunisia, Libya and Mauritania) have shown striking differences in breast cancer patterns.          
Age-standardized incidence per 100,000 for breast cancer in 2002 was 23.5 in Algeria versus 
91.9 in France. The size and grade of breast tumors in the Maghreb was increased, while the 
median age of onset (48) was more than ten years younger than the European/North American 
median of 61. About 11 % of breast cancer cases in Algeria occur in women < 35 years old, and 
55 % of cases at < 50 years. The differences may be due to differences in exposure to female 
hormones, diet, physical activity, or other factors. The germline mutations of breast cancer 
susceptibility genes (BRCA1) and breast cancer susceptibility genes (BRCA2) have been 
associated with a significant increase in breast cancer risk and certain other cancers. Among the 
most known mutations in these tumor suppressor genes are 5382insC and 185delAG in BRCA1 
and 6174delT in BRCA2 [122]. 
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It was indicated that the aforementioned founder mutations were not detected in the groups 
studied. The results indicate that 5382insC and 185delAG mutations in BRCA1 and 6174delT in 
BRCA2 have much less frequency in Iranian breast cancer patient [123]. 
 Thirty patients with early onset breast cancer or familial breast cancer from Malaysia 
were analyzed for germline mutation in the early onset breast cancer gene (BRCA1). Direct 
sequencing of the entire coding region of BRCA1 identified a frame shift mutation, c.5447-
5448insC (insC5447) (codon 1776 of exon 21) in a patient aged 32 of the Malay ethnic origin, 
who had no family history of breast and/or ovarian cancer. Eight polymorphisms (2201C>T, 
2430T>C, P871L, E1038G, K1183R, 4427T>C, S1613G and IVS8- 57delT) were identified in 
the samples tested [125]. 
Early onset breast cancer susceptibility gene (BRCA1) has been linked to 52% of families 
with breast cancer [125, 126]. Germline BRCA1 mutations have been identified in young-onset 
breast cancer patients without a strong family history of breast cancer. Greenman et al., reported 
BRCA1 mutations in 18% patients (five out of 27) with families with one to three relatives with 
breast or ovarian cancer [127]. Another study identified 15 mutations from 208 breast cancer 
patients below the age of 45 who had first degree breast cancer family history (affected mother 
and/or sister with breast cancer [128]. 
Germline mutations in the BRCA1 or BRCA2 genes predispose their carriers to breast or/and 
ovary cancers during their lifetime. The most frequent mutations: 5382insC, 185delAG, C61G 
and 4153delA in BRCA1, and 6174delT and 9631delC in BRCA2 were studied in a group of 148 
probands admitted for genetic counseling, using allele-specific amplification (ASA) PCR test. 
Fifteen carriers of three different mutations: 5382insC, 185delAG and C61G in BRCA1 were 
found. Two families carried the 185delAG mutation and additional two C61G in BRCA1. 
Nobody carried the mutation 4153delA in neither BRCA1 nor 6174delT or 9631delC in BRCA2. 
Most of the carriers of a germline mutation were observed among the patients who developed 
bilateral breast cancer (17%). The lowest frequency of the germline mutations was found in the 
healthy persons who had two or more relatives affected with breast or ovarian cancer. A few 
recurrent mutations which accounted for more than 80% of all germ-line mutations described in 
the Polish population. The most important finding in both papers was a very high frequency of 
single BRCA1 5382insC mutation. Mutations 185delAG and C61G were less frequent. A 
recurrent mutation was earlier described also in the BRCA2 gene–9631delC [129]. It was likely 
that this particular mutation is limited to the Southern part of Poland because all families carrying 
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this mutation lived in Silesia and came from Silesia or a neighboring district. In this group of 
patients we did not find any family with this mutation. It confirmed the distribution of recurrent 
mutations in the Polish population and it is not different from the rest of Poland [130]. 
A large number of distinct mutations in the BRCA1 and BRCA2 genes have been reported 
worldwide, but little was known regarding the role of these inherited susceptibility genes in 
breast cancer risk among Indian women. Indian breast cancer patients were selected with regard 
to early onset disease (≤40 years) and family history of breast and ovarian cancer. Two hundred 
four breast cancer cases along with 140 age-matched controls were analyzed for mutations. In 
total, 18 genetic alterations were identified. Three deleterious frame-shift mutations (185delAG 
in exon 2; 4184del4 and 3596del4 in exon 11) were identified in BRCA1, along with one 
missense mutation (K1667R), one 5'UTR alteration (22C>G), three intronic variants (IVS10-
12delG, IVS13+2T>C, IVS7+38T>C) and one silent substitution (5154C>T). Similarly three 
pathogenic protein-truncating mutations (6376insAA in exon 11, 8576insC in exon19, and 
9999delA in exon 27) along with one missense mutation (A2951T), four intronic alterations 
(IVS2+90T>A, IVS7+ 75A>T, IVS8+56C>T, IVS25+58insG) and one silent substitution 
(1593A>G) were identified in BRCA2. Four previously reported polymorphisms (K1183R, 
S1613G, and M1652I in BRCA1, and 7470A>G in BRCA2) were detected in both controls and 
breast cancer patients. Rare BRCA1/2 sequence alterations were observed in 15 out of 105 
(14.2%) early-onset cases without family history and 11.7% (4/34) breast cancer cases with 
family history. The BRCA1 and BRCA2 mutations appear to account for a lower proportion of 
breast cancer patients at increased risk of harboring such mutations in Northern India (6/204, 
2.9%) than has been reported in other populations [131].  
Despite substantial differences in age-standardized incidence rates between developed and 
developing countries (age standardized rates per 100,000 women (ASR) ranging from 99.4 to 
16.5 in North America and Central Africa, respectively). In all, breast cancer accounts for 14.1% 
of female cancer deaths. Most alarmingly, incidence rates have continued to increase worldwide, 
with an overall annual increase of approximately 0.5% since 1990. However, changes in 
incidence rates are greatest in developing countries, attaining annual increases of 3–4%. Should 
these trends continue, it is estimated that 1.5 million new cases of breast cancer will be diagnosed 
in 2010 [132]. 
In India, an average of 80,000 women was diagnosed with carcinoma of the breast, and 40,000 
women die of the disease every year [133].  
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To date 1536 distinct mutations, polymorphisms and variants in BRCA1 and 1885 in 
BRCA2 have been reported [BIC database, [134], which are distributed throughout the entire 
coding regions of both genes. Together, mutations in both the genes account for the great 
majority of families with hereditary susceptibility to breast and ovarian cancer [126]. 
Epidemiological studies indicate that BRCA1 mutation carriers have a lifetime risk of breast 
cancer that is on the order of 60–80%. The lifetime breast cancer risk for BRCA2 mutation 
carriers approaches that of BRCA1 carriers: however, disease onset has been documented to be at 
a later age [126, 135].  
In other words, women with an altered BRCA1 or BRCA2 gene are 3 to 7 times more likely to 
develop breast cancer than women without alterations in those genes [136], with very high 
relative risks for early disease onset (before age 40) of about 30-fold. Carriers of BRCA1 and 
BRCA2 mutation(s) are also at increased risk for other cancers – in particular, both genes increase 
the risk of ovarian cancer, while BRCA2 confers greatly increased risks of male breast cancer. 
Additional, but more modest risks are found for uterine, cervical, early onset prostate and 
pancreatic cancers for BRCA1 [137], and prostatic, pancreatic, gallbladder, bile duct, stomach 
cancers and melanoma for BRCA2 [138]. 
However, the contribution of mutations in these two genes to breast cancer patients in the 
Indian population remains relatively unexplored apart from a few small studies [139, 140]. The 
BRCA1 185delAG mutation was identified in an early onset index case [age 35] without any 
family history. This mutation is common in Ashkenazi Jews, having attained a 1% carrier 
frequency within the population [141]. Population studies have shown that the 185delAG 
mutation predates the separation of Sephardi and Ashkenazi Jewish populations and is probably 
2000 years old [142]. 
In follow-up studies of other families, they have now identified this mutation in seven unrelated 
Finnish families. The other recurrent mutations, the exon 18 nonsense mutation (8555TG) and 
the Of the 10 BRCA1 mutations identified here, six are so far novel Finnish mutations while four 
have been described previously in other European populations or in the USA. [143].  
 Of these, 2803delAA (also called 2804delAA) is a prominent founder mutation in the 
Netherlands and Belgium, but has not been found previously in other populations [144]. Another 
mutation, 3604delA, has been described in Dutch and German families [144, 145]. The 5385insC 
(also named as 5382insC) mutation found in one Finnish family has been described as a founder 
mutation in Russia [146], and in Hungary [147], in families of Jewish and non-Jewish ancestry. 
Finally, the 4446CT mutation in exon 13 has been found multiple times on different haplotypes 
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and may represent a mutational hotspot [148]. Of the six different BRCA2 mutations, five were 
novel mutations so far unique to Finland, while one recurrent, and a proposed ancient founder 
mutation (999del5), has been previously described as a strong founder in Iceland [149-153]. 
 
2.10 Breast cancer in Gaza Strip 
Breast cancer is a common malignancy affecting women around the world, including Gaza Strip. 
No studies on breast cancer has been published. This is the first study that documents collected 
data about cancer patients.      
 
Figure 2.1 Most common types in female malignancies. Palestinian National Authority-MOH-
Gaza Cancer Registry Center-Reported Cases 2003 [154]. 
• The incidence of cancer cases in the whole population is about 40/100.000. 
• The median age of cancer in female was 52 years and most common types Figure 2.1 
were: 
Breast 39%, Colorectal 8%, leukemia 6% Thyroid 5%, Lymphoma 4%, Uterus 4%, Bone 3%, 

























Materials and methods 
3.1 Study design 
This study is a cross sectional study. 
3.2 Study population 
The study population comprised 122 breast cancer patients in El- Shifa Hospital and The 
European Hospital of Gaza Strip in the period between March 2010 to July 2010 and control 
sample consist of 55 married healthy females. Only 94 samples of breast cancer patients were 
processed and analyzed in the genetic laboratory at the Islamic University of Gaza. 
3.3 Questionnaire 
The questionnaire (see Annex 1) has been filled by all  patients and agreement to carry out 
mutational genetic analysis has been signed on the questionnaire papers. It concluded the risk 
factors associated with breast cancer risk such as the age of patients, the height and length to 
calculate the BMI, the age at menarche, the age at first birth, number of pregnancies, Time of 
breast feeding of the population of the study, using of contraceptives, the age of onset of the 
disease of the patients, and the family history of the study population. 
3.4 Permission and ethical considerations 
According to research ethics, permission was obtained from Helsinki committee (Annex 2) and 
MOH (Annex 3) for specimen collection and performing the study. The objective of the study 
was explained to all participants and their consent was taken. The age of the women of the study 
population was under 50 years old. 
3.5 Materials 
3.5.1 Chemicals and Reagents 
The chemicals and reagents used in this study are summarized in Table 3.1. All chemicals were 




Table 3.1. Chemicals and reagents used in the present study 
Reagent supplier 
Wizard Genomic DNA purification Kit PROMEGA, Madison, WI, USA 
Absolute Ethanol Sigma, USA 
Isopropanol Alcohol Sigma, USA 
Agaros PROMEGA, USA 
Taq DNA polymerases PROMEGA Cat. # M-1661. 
PRONTO® Kits Pronto diagnostic. Isreal 
 
3.5.2 Disposables 
The major disposables used in this study are listed in Table 3.2. 
Table 3.2.  List of disposables 
Item Supplier 
2.5 K3-EDTA Tube Canelli, Italy 
Disposables powder gloves Weihai Sun Genius – China 
Micro Tubes, 1.5 ml capacity Labcon, USA 
Micro Tubes, 0.2 ml capacity Labcon, USA 
Micropipettes tips Labcon, USA 
 
3.5.3 Equipments 
All experiments of this study were done at the Islamic University of Gaza- Genetic Laboratory. 
The major equipment that were used are listed in Table 3.3. 
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3.6 Methods  
3.6.1 Case  selection 
 
Selection of patients mainly based on the following criteria: any patient with breast cancer 
diagnosed under the age of 50 years; any patient having a family history of breast, and any 
patient had a previous personal history of cancer.  
3.6.2 Blood sample collection 
Peripheral blood samples (5 -.10 ml) was  collected in  EDTA Tube. The buffy coat was 
separated and frozen at - 70°C for further use. 
3.6.3 DNA extraction 
Genomic DNA was  extracted from peripheral blood. Promega' DNA Extraction kit features a 
rapid, procedure for isolating DNA from whole blood that is ready for direct use in DNA 




Thermocycler Eppendrof, Germany 
Microcentrifuge Centurrion Scientific LTD, UK 
Refregerator -20ºC LG, Koriaad, USA 
Vortix Mixer Turbo Mixer, Georgia 
Micropipette Lab Mate, Poland 
Microwave Nanodrop, USA 
Safety Cabinet Heraeus, Germany 
UV-Transilluminator Scie- pals LTD, UK 
Electrophoresis BioRad, USA 
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3.6.3.1  Red blood cell lysis 
1. Nine hundred microliter of cell lysis solution was combined with three hundred microliter   
blood in a tube (mixed by inversion) then it was incubated for ten minutes at room 
temperature. 
2. The tube was centrifuged 13000xg; twenty seconds. 
3. Supernatant was discarded, then pellet was vortex. 
3.6.3.2 Nucleic lysis and protein precipitation 
1. Three hundred microliter of nucleic lysis solution were added and mixed by inversion. 
2. One hundred microliter of protein precipitation solution were added then vortex for 
twenty seconds. 
3. The tube was centrifuged 13000 x g; three minutes. 
  3.6.3.3 DNA precipitation and rehydration 
1. The supernatant was transferred to a new tube containing three hundred microliter 
isopropanol then mixed. 
2. The tube was centrifuged 13000 x g; one minutes. 
3. Supernatant was discarded, then three hundred micrometer ethanol (70%) were added. 
4. The tube was centrifuged 13000 x g; one minutes. 
5. The ethanol was aspirated and air- dried the pellet (10- 15 minutes ). 
6. The DNA was rehydrated in one hundred microliter of DNA rehydration solution for one 
hour at 65˚C or over night at 4˚C then it was refrigerated for further use.  
3.6.4  Mutation detection 
Design of  PRONTO technology 
  The Pronto system allows detection of disease causing mutations and Single Nucleotid  
Polymorphisms (SNPs) in DNA sequences. The PRONTO technology is based on a single 
nucleotide primer extension assay that is visualized by ELISA in a 96-well format. Its accuracy 
comes mostly from the high specificity in which DNA polymerase incorporates nucleotides into 
the elongating strand. In the detection process, a 5labeled primer binds to the tested DNA (post 
PCR) next to the suspected mutation site. DNA polymerase extends the 5labeled primer with a 
single biotinylated nucleotide. The mutation site is tested in two separate reactions on a 
thermostable 96 well microplate  (see Annex 4). 
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 Each reaction utilizes a different complementary bio-dNTP for the normal and the mutant 
alleles. Only the extended primers are labeled with biotin (see Annex 5).Mutation detection was 
carried out using Pronto diagnostic commercial kit which include the following steps: 
3.6.4.1 DNA amplification: 
 Amplification of target DNA to visible levels (10-100 ng/ μl) on an EtBr-stained gel is 
recommended. It include the following steps;  
1- Tow microliter template DNA (from an initial concentration of about 150 ng/μL) were 
dispensed to a thermoplate well or tube. 
2- A master mix were prepared in a sterile vial, according to the volumes indicated in the table 
below, plus one spare reaction volume. The Taq DNA polymerase was added to the amplification 
mix shortly before dispensing the mix. And gently mixed by pipetting in and out several times. 
3.a PCR master mix 
Solution Volume for one sample 
Amplification mix BRCA 17.5 μL 
Taq DNA Polymerase (5 u /μL) 0.5 μL 
 
Taq DNA polymerases were validated for use with this procedure (lacking 3 → 5 exonuclease 
activity): PROMEGA Cat. # M-1661. 
3-  Eighteen microliter  master mix was dispensed to each well or tube. 
4- One drop of ColoRed-Oil was added to each well.  
5- The thermo plate well or tube was placed in a thermocycler previously programmed with the 
following protocol: 
3.b Cycling protocol 
Start,               1. 94º C                 2 minutes 
35 cycles,        2. 94º C                 30 seconds 
                       3. 59º C                 30 seconds            
                       4. 72º C                  60 seconds 
End,                5. 72º C                 5 minutes 
To verify amplification, five microliter of the amplified product were subjected to electrophoresis 
in a 2% Agarose gel. 
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3.c Sizes of amplified fragments 
Gene Position  Mutation Fragment size 
BRCA1 Exon 2 185 delAG 258 bp. 
BRCA1 Exon 20 5382 insC 400 bp. 
BRCA2 Exon 11 6174 delT 550 bp. 
 
3.6.4.2 Post - amplification treatment 
This reaction inactivated free nucleotides, which was remain after the amplification steps: 
1- A post-amplification treatment mix was prepared shortly before use. Combined in a single test 
tube the volumes appearing in the following table, (multiplied by the number of tested samples, 
plus one spare volume) . 
* Solution volumes for one sample 
         1. PRONTO  Buffer 3               45.0 μL 
         2. Solution                                 2.0 μL 
         3. Solution D                             1.5 μL 
2-  Gently by pipetting this solution was mixed in and out five times. 
3- Forty microliter of the post-amplification mix were added into each well or tube containing 
fifteen microliter of each amplified DNA sample. 
4- One drop of ColoRed oil was added to each tube.  
5- The tubes were incubated for thirty minutes at 37◦C, then for ten minutes at 95◦C in a 
thermocycler (see Annex 6). 
3.6.4.3 Primer extension reaction 
This post-amplification mutation detection system utilizes a single nucleotide primer 
extension assay. It benefits from the high specificity with which DNA polymerase incorporates 
nucleotides into the elongating strand. In the complete genotyping format of the PRONTO  
system each mutation site is tested in two wells of a 96-well microtiter plate. Every sample is 
separately and internally controlled for each mutation tested.  DNA polymerase extended  a 5 
FITC-labeled primer with a single biotinylated nucleotide, which was complement the nucleotide 
at the tested site. Every reaction utilized a different complementary bio-dNTP for the normal and 
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the mutant alleles. Each mutation is tested in two wells: one for the mutant allele and one for the 
wild-type allele. The amplified DNA is dispensed into a 96-well thermowell plate using a 
multichannel pipette (see Annex 7). The plate is placed in a thermocycler, where a short primer 
extension reaction takes place as shown in Figure 3.1. 
Results are clearly determined visually. 
 
                                                      
                                                                         Figure 3.1  primer  extension  reaction. 
1- The thermocycler was programmed as follows: 
Cycle            Temperature          Time 
Start:                94ºC                     15 sec. 
20 cycles:         94ºC                    30 sec. 
                         57ºC                    10 sec. 
End:               18-25ºC - Cool down to room temperature 
 2-  A PRONTO plate  was taken out of its pouch.  
3-  Eight microliters of post-amplification treated DNA were dispensed into the first six wells in 
The first row. Continued with the remaining samples.  
4- The plate was titled and then added one drop of ColoRed oil to each well. 
5- The thermocycler was turned on and started the cycling protocol. 
6- When the thermal cycling is complete, you can proceed to the ELISA assay, or store the 




3.6.4.4 Elisa assay- color development 
3.A. Detection by ELISA 
             Reaction products were diluted and transferred to a streptavidin coated 96-well ELISA 
plate. Following a short incubation period, unbound 
primers were washed away and an HRP anti-FITC 
conjugate is added. The peroxidase reaction, that 
takes place in the presence of the HRP substrate, 
resulted in the appearance of a deep blue color in 
every positive well. Each well of a PRONTO Plate 
contains 5´-labeled primers that hybridize to the 
tested DNA next to the suspected mutation sites, 
and biotinylated nucleotides (bio-dNTPs), which are                      
complementary to the nucleotide bases at the tested        
sites.  
Depending on the tested individual’s genotype, the relevant primers are extended and thus 
become labeled with biotin as in Figure 3.2. 
The ELISA assay consists of the following steps:  
 Binding the biotinylated primer to the 
Streptavidin-coated plate Figure 3.3. 
  Washing away the unbound primer.     
  Incubating with the HRP conjugate. 
  Washing away the unbound conjugate. 
  Incubating with the TMB substrate 
 (color development).                                                    Figure 3.3 ELISA assay of biotinylated 
primer 
The results of this assay were determined  Visually, by monitoring the development of the blue 
color. 
3.B. Preparation 
1- The 20x wash solution were diluted  to 1x with deionized water. 
2- The plastic cover of the detection plate were peeled off . The side of the plate was marked  
with the kit name and test number. 
Figure 3.2 labeled primers with biotin. 
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3- The PRONTO plate was placed and the detection plate side by side, oriented in the same 
direction. 
3.C. Transfer to the detection plate 
1- A reagent reservoir /trough was filled with the green colored assay solution. 
About eleven microliter will be required for a 96-well plate. 
2- One hundred microliters of Assay Solution were added to the bottom of each well in column 1 
of the PRONTO plate with a multichannel pipette. We mixed the assay solution with the solution 
in the wells. 
3- One hundred microliters from each well in this column without changing tips, were transferred 
to the first column in the detection plate . 
4- This procedure was repeated, using a new set of tips for each column. It is essential to 
maintain the order of the samples. 
5- The PRONTO plate was incubated  for ten minutes at room temperature (18-25ºC). 
3.D. Visual genotype assignment  
For every 
mutation site tested, at 
least one of the wells 
should develop a deep blue 
color. 
Otherwise, results are 
invalid  Figure 3.4.                                                                                         
 
       









3.6.4.5 Genotype assignment according to visual inspection of test results 
Genotype assignment according to visual inspection of test results as in figure 3.5. 
                                   
Figure 3.5 Visual inspection of test results. 
 
3.7 Statistical analysis 
Both qualitative and quantitative data analysis methods were used. The data analysis were made 
utilizing  SPSS version 16.  
Statistical analysis test  for analysis of binominal variables outcome (dependent variable) the 
study used the following tests: 
 Count, percentage and descriptive statistics. 
 Odds ratio which used to show the difference in risk between independent 
variables (groups) 
 Chi–square test to build 2x2 tables for categorical data and cross tabulation and 
examine if there is statistically significance proportion differences. 







4.1 Risk of breast cancer associated with reproductive health determinants for 
sporadic and hereditary patients. 
4.1.1 Patients’ age groups 
The study population has been divided into two groups, a control group of 55 individual and 
breast cancer patients group which consist of 122 patients. Both groups have been divided 
according to age into two groups as shown below in Table 4.1. 






It was found that more than 41.2 % of the patients were < 40 years. The mean age of the study 
population is 40.3 ± 7.9 as shown below in Table 4.2. 
Table 4.2. Statistical descriptive of the population under study 
Na*mean non of them. 
 











Mean Maximum  Minimum  
7.9 40.3 50 22 Age (years) 
5.9 29.2 53.1 17.9 BMI  (kg/ m2) 
1.4 13.7 18 11 Age at menarche (years) 
6.6 20.3 42 Na* Age at marriage (years) 
8.5 20.7 43 Na* Age at first birth (years) 
0.3 1.1 2 1 Have been pregnancy 
3.7 3.5 16 Na* Number of pregnancy 
0.4 1.2 2 1 Breast feeding 
1.2 1.9 4 Na* Time of feeding (years) 
0.4 1.8 2 1 Using of contraceptives 
5.9 39.6 50 25 Age of onset of disease (years) 
0.5 1.5 2 1 Parents  consanguinity 
0.5 1.5 2 1 If there is relatives with cancer 
    Valid N =177 
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Table 4.1 revealed that there was statistical significant relationship between the control individual 
and breast cancers patients related to women age group (P= 0.00) and OR= 0.14 with confidence 











                  
Age 
Figure 4.1 The frequency of age of the population under study. 
Also when we compare the patients of mutated and non- mutated in BRCA1/2 genes as shown 
below in Table 4.3. The results revealed a statistical significant relationship between breast 
patients related to women age group (P= 0.05) and OR ratio = 2.6 with confidence interval 1.04 - 
6.50 at 95%. This means that women with age >40 years has 2.6 times hazard risk having BC 
compared with women <40 years which indicating the incidence of mutations tend to increase 
with the age of patients ≥ 40. 
  


















4.1.2 Patients’ body mass index (BMI) 
The patients' weight ranged from 41 kg to 136 kg. Patients have been grouped based on BMI into 
underweight, normal, obese, and overweight. The minimum BMI was 17.9, the maximum BMI 
was 53.1, with a mean of 29.2± 5.9 as shown in Table 4.2. 
Both patients and controls BMI has been classified into two groups BMI under 28 has been 
considered normal within the normal range and BMI above 28 has been considered within 
abnormal weight range. There is statistical significant difference between the two groups in 
relation to BMI (P= 0.04) with confidence interval 0.28-1.00 as shown below in Table 4.4. This 
mean  that breast cancer incidence increase with the increase of the BMI of the individual. 
  






*OR= odds ratio, CI= confidence interval 
4.1.3 Age at menarche 
The minimum age of menarche was found to be 11 years and the maximum age of menarche is 
18 years, with a mean age of 13.7±1.4 as shown in Table 4.2. When they grouped it was found 
that 83 (46.9%) of the patients their ages at menarche were at ≤13 years old while 94 (53.1%)of 
the patients their ages at menarche were at >13 years old and there were no statistical significant 
relationship between control cases and the patients related to the age at menarche (P= 0.46) as 
shown in Table 4.5. 
P- value ( 95 % CI)** OR** BC patients Normal   
49 31 
61.2% 38.8% 
< 28  
 
73 24 
0.04* (0.28-1.00)  0.53 
75.3% 25.0% 
≥ 28  
BMI 
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Also there was no statistical significant relationship between of mutated and not mutated breast 
cancer patients related to women age at menarche (P= 0.68) as shown in Table 4.6. 







*OR= odds ratio, CI= confidence interval. 
4.1.4 Age at marriage 
Only 9 of the patients were single, 113 patients were married as shown in Table 4.7, the 
minimum age of married was 13 years and the maximum was 42 years of age. The mean age of 
marriage was 20.3± 6.6 as shown in Table 4.2. 
Table 4.7. Social status of the population under study 
Cumulative 
Percent Percentage % Number  
92.6 94.9 168 Married 
100.0 5.08 9 Single 
 100.0 177 Total 
 
P- value ( 95 % CI)** OR** BC 
patients 
Normal   
58 25 























4.1.5 Age at first birth 
It was found that 19 of patients have never been pregnant and the rest were pregnant. The 
minimum age at first birth was 16 years and the maximum age at first birth was 43 years old as 
shown in Figure 4.2. The mean age of first birth was 20.7± 8.5 as shown in Table 4.2. 
 
 
Figure 4.2. The frequency of age at first birth.  
  
There were no statistical significant relationship between control individual and breast cancer 
patients related to the age at first birth (P= 0.38) as shown in Table 4.8.  







But there were statistical significant relationship between breast cancers patients related to 
women age at first birth (P= 0.04) which in the other hand the result indicated the OR ratio was 
2.6 with confidence interval 1.12 – 5.96 at 95% this means that women with age more than 20 
years of  age at first birth has 2.6 times hazard risk having breast cancer compared with women 
their age at first birth was less than or equal 20 years as shown in Table 4.9. 
 
 
P- value ( 95 % CI)** OR** BC 
patients 










Age at first 
birth 
 
43 39 38 36 35 34 33 31 30 28 27 26 25 24 23 22 21 20 19 18 17 16 






















*OR= odds ratio, CI= confidence interval. 
4.1.6 Number of pregnancies 
There were 19 patients had not been pregnant at any time during their life as shown in Table 
4.10. The number of pregnancies of patients had ranged from Na*-16 times which showed a 
mean of 3.5±3.7 as shown in Table 4.2. 
Table 4.10. Patients and pregnancy 
Cumulative 
Percent Percentage % Number 
  
89.26 89.26 158 Yes 
100.0 10.73 19 No 





The result revealed that there was statistical significant relationship between breast cancer 
patients and control individual related to the number of pregnancy (P= 0.00) within confidence 
interval 0.12-0.55 as shown in Table 4.11. 
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P- value ( 95 % CI)** OR** BC 
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87 32  
0.00* (0.12- 0.55) 0.26 
73.1% 26.9% 
> 3 
No. of  pregnancies 
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When we compared the patients who are mutated and non- mutated in BRCA1/2 genes, there 
were  no statistical significant relationship (P=1.0) as shown in Table 4.12. 





*OR= odds ratio, CI= confidence interval. 
4.1.7 Breast feeding 
From 158 individual were pregnant, there were 157 patients had fed their children, there are just 
one patients had not feed their children. The total number of patients who did not feed their child 
was 20 patients (15.8%) as shown Table 4.13. The mean of the study population 1.2± 0.4 as 
shown in Table 4.2. 
Table 4.13. Feeding or not of the study population 
Cumulative 
Percent Percentage % Number 
  
88.7 88.7 157 Yes 
100.0 11.3 20 No 
 100.0 177 Total 
Feeding or not 
 
The study population has been divided into two groups, there were statistical significant 

































There was no statistical significant relationship between breast cancer patients related to duration 
of breast feeding (P= 0.65) as shown in Table 4.15. 









4.1.8 Use of contraceptives 
As 168 had married and 103 were pregnant, so 132 had not use contraceptives and 45 patients 
had contraceptives. The mean of the study population 1.8± 0.4 as shown in Table 4.2. When 
compared between the control individual and breast cancer patients related to the use of 
contraceptives, there was statistical significance (P= 0.01) as shown in Table 4.16. 
 





*OR= odds ratio, CI= confidence interval. 
P- value ( 95 % CI)** OR** BC 
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0.65 (0.32 - 1.99) 0.79 
51.0% 49.0% 
> 1 yr 
 
Time 
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feeding 
 
P- value ( 95 % CI)** OR** BC 
patients 
Normal   
36 27 
57.1% 42.9%  
Yes   
86 28  







However, there was no statistical significant relationship between breast cancer patients related to 
use of contraceptives (P= 0.26) of mutated and not mutated patients as shown in Table 4.17. 






*OR= odds ratio, CI= confidence interval. 
4.1.9 Age of onset of disease 
The minimum age of onset of cancer was 25 years, the maximum age of onset was 50 years, and 














Figure 4.3. Frequency of onset of the disease. 
As shown in Figure 4.3 the most frequency of onset of the disease among the breast cancer 

































 The number of patients their ages  of onset < 40 were 52 (42.6%), and the number of patients 
their ages of onset ≥ 40 were 70 (57.4%)  as shown in Table 4.18. 
Table 4.18. Age of onset the disease pf patients 
Cumulative 
percent Percentage % Number   
42.6 42.6 52 < 40 
100.0 57.4 70 ≥ 40 
 100.0 122 Total 
Age of onset 
 
 
There was statistical significant relationship between breast cancers patients related to women 
age of onset of disease (P= 0.00) which in other hand the result indicated the OR ratio was 4.1 
with confidence interval 1.74 - 9.77 at 95% this means that women with age more than 40 years 
of onset of disease has 4 times hazard risk having BC compared with women less than 40 years 
as shown in Table 4.19. 
Table 4.19. Risk of breast cancer associated age of onset of disease of patients 
 







0.00* (1.74 - 9.77) 4.1 
67.3% 32.7% 
≥ 40 
Age of onset 
 
 










4.2 Familial history 
4.2.1 Parents’ consanguinity 
It was found that 86 (48.6%) of the patients their parents were relatives, and the rest 89 
patients (51.4%) their parents were not related to each other. The mean of the study population    
1.5± 0.5 as shown in Table 4.2. There were no statistical significant relationship between the 
mean groups relates to the parents consanguinity as shown in Table 4.20. 






*OR= odds ratio, CI= confidence interval 
4.2.2 Familial cases 
Out of the 177 individual, there were 76 (42.9%) of the individuals had relatives with cancer 
while 101 (57%) did not have any relatives with cancer, as shown in Table 4.21. There was 
statistical significant relationship between breast cancers patients and control individual related to 
women age of onset of disease (P= 0.00) which in other hand the result indicated the OR ratio 
was 5.1 with confidence interval 2.45 – 11.48 at 95%. 
Table 4.21. Risk of breast cancer associated with relatives with cancer of the study population 
 
*OR= odds ratio, CI= confidence interval 
There were 2 patients had relatives from all kinds of relatives, 12 patients had relatives from first 
and second degree relatives, one patient had relatives from first and third degree relatives, and 
one patient had relatives from second and third degree relatives. The number of patients with  























only first degree relatives were 13 (39.3%), while patients with only second degree relatives with 
cancer were 13 (44.3%), and patients with only  third degree relatives who have cancer history 
were 9 patients (16.4%) as shown in Table 4.22. 
 Table 4.22. Number of relatives with cancer of the breast cancer patients  














There was no statistical significant relationship between breast cancer patients related to relatives 
with cancer (P= 1.0) and first degree relatives with cancer (P= 0.83) as shown in Table 4.23. 
Table 4.23. Risk of breast cancer associated with relatives with cancer specially first degree 
relatives of the patients 




















 relatives with cancer 
 
 




4.2.3 BRCA1 and BRCA2  mutations 
We managed genetic analysis for 94 patients from the population under study (122 patients). The 
number of the patients with mutations were 49 patients ( 52.1%) and the rest 45 patients (47.9%) 
were normal (wt) as shown in Table 4.24. 
Table 4.24. Percentage of normal and mutated of patients 
Percentage % Number  
47.9 45 Wilde type (wt) 
52.1 49 Mutated (mt) 
100.0 94 Total 
 
There were 24 patients had BRCA1 (49%), 13 patients had BRCA2 (26.5%) and 12 patients had 
both mutations (24.5%) as shown in Table 4.25. 
Table 4.25. Percentage of the mutations of the patients 
Percentage % Number   
49.0 24 BRCA1 
26.5 13 BRCA2 
24.5 12 Both 




4.2.3.1 BRCA1 mutations 
A. 158AG mutation 
There were 2 patients had the three mutations, 17 patients had two mutations, and the rest (30 
patients) had one mutation. We found 25 patients had BRCA2 mutation (51%) and 24 patients 
had BRCA1 mutations (49%). The number of patients with 158AG mutation were 60, 37 patients 









Table 4.26. Percentage of the 158AG mutation of the patients 
 
Percentage % Number   
61.7 37 Normal 
16.7 10 Heterozygous 
21.7 13 Homozygous 




B. 5382C mutation 
The number of patients with 5382C mutation were 57, 35 patients were normal homozygous, 17 
patients were heterozygous and 5 of them were homozygous mutant as shown in Table 4.27.  
Table 4.27. Percentage of the 5382C mutation of the patients 
 
Percentage % Number   
61.4 35 Normal 
29.8 17 Heterozygous 
8.8 5 Homozygous 




4.2.3.2 BRCA2 mutation 
A. 6174T mutation 
The number of patients with 6174T mutation were 48 normal homozygous, 12 were found to be 
heterozygous while the rest 13 patients were found homozygous as shown in Table 4.28. 
Table 4.28. Percentage of the 6174T mutation of the patients 
 
Percentage % Number   
47.9 23 Normal 
25.0 12 Heterozygous 
27.1 13 Homozygous 










5.1 Age of patients and breast cancer 
Breast cancer is the first occurring type of cancer in women in Gaza Strip. As known 
earlier studies have discussed the risk factors which lead to high rate of incidence, we aim in this 
study to discuss the main risk factors of breast cancer. 
 Worldwide studies have shown that breast cancer increases with age specially after 40 
years of age. In our study it seems that our population is not different from other populations and 
that the incidence of breast cancer increase with age as compared between patients < 40 and 
patients ≥ 40. 
 Also the incidence of the mutation causing breast cancer in patients has been shown to 
increase with age. This contradicts  earlier study on Arab population in Israel which showed that 
mutation incidence increases before the age of 50. This indicate that mutation tend to be somatic 
rather than inherited. This could be due to the different environmental disturbances that the Gaza 
population are exposed to that come from continuous explosives and attacks by Israel. 
The mean age of the study population was 40.3±7.9. The incidence of patients their ages 
were < 40 (25.5%) and 74.5% of patients with ages ≥ 40. There was a statistical significant 
relation related to women age between the control and the patients (P= 0.00), hazard ratio OR= 
0.14  [95%CI=0.07-0.29], and between mutated and not mutated of the breast cancer patients (p= 
0.05), hazard ratio (OR)= 2.6  [95%CI=1.04-6.49]. It was reported that breast cancer incidence is 
very low before age 25, and increases up to 100 fold by age 45 [86]. 
5.2 BMI and breast cancer 
In order to study the relation between BMI and breast cancer incidence we divided patients in 
two groups according to their BMI. ≤ 20 group which include normal and under weight patients 
and > 20 group which include overweight and obese patients. Statistical analysis showed an 
association between rate of BMI and breast cancer incidence. Another study suggested that 
weight loss in early adult life (age 18 to 30) protects against early-onset BRCA-associated breast 
cancers. Weight gain should also be avoided, particularly among BRCA1 mutation carriers who 





5.3 Age at menarche and breast cancer 
Age at menarche was suggested to be a strong and consistent prediction of breast cancer 
risk in the general populations. However our results showed that in cancer patients there was no 
association between age at menarche and incidence in breast cancer in this population. That study 
was consistent with other population in which this relation has been observed. Although a study 
has shown that early age at menarche is determinant of breast cancer among women with BRCA1 
mutations [92- 95]. 
     Our study showed that age at menarche have no risk effect on breast cancer incidence 
among women with BRCA1 and BRCA2 mutations. 
5.4 Age at first birth and breast cancer  
The younger the women is when she begins childbearing, the lower the risk of breast cancer.  The 
relative risk of developing breast cancer is estimated to increase by 3 % for each year of delay. 
There is evidence that reduction in risk of breast cancer with childbirth, and higher risk 
with later age at first full time birth, may be limited to estrogen reception positive tumors. This 
has been confirmed in mutated and not mutated patients, as the odd ratio for the risk of breast 
cancer in mutated related to age at first birth was found to be OR= 1.2 [95% CI= 0.59-.2.45] 
when we compared patients under and over 20 years of age at first childbirth. There was no 
association between breast cancer incidence and age at first birth between the control and the 
patients (P= 0.38). 
 However, this association has been observed in other population. In BRCA2 mutation 
carriers, first childbirth at later ages was associated with an increased risk of breast cancer 
compared with first childbirth before age 20 years (20 – 24 years, hazard ratio [HR] = 2.33 [95% 
CI = 0.93 to 5.83]; 25 – 29 years, HR = 2.68 [95% CI = 1.02 to 7.07]; ≥ 30 years, HR = 1.97 
[95% CI = 0.67 to 5.81]), whereas in BRCA1 mutations carriers, first childbirth at age 30 years or 
later was associated with a reduced risk of breast cancer compared with first childbirth before age 
20 years (HR = 0.58 [95% CI = 0.36 to 0.94]. [91] 
5.5 Breast feeding and breast cancer 
Earlier studies has shown that Women who breastfeed reduce their risk compared with women 
who do not breastfeed. The longer a woman breastfeeds, the greater the protection: risk is 
reduced by 4% for every 12 months of breastfeeding. However we found that the numbers of 
breast cancer patients who fed for more than one year higher than the number in normal 
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population. There is no statistical significant relationship between breast cancer patients related to 
duration of breast feeding (P= 0.65). 
This contradiction could be due to several reasons i.e. the duration of breast feeding as we 
did not calculate the total duration of breast feeding or because other studies use the cut time of 
duration of breast feeding from three months [155]. 
5.6 Oral contraceptives and breast cancer 
In cancer patients ̓ population the findings that more women use oral contraceptives than normal 
population. This correlation does not seem to agree with the findings of our study as there was no 
statistical significant relationship between breast cancer patients related to use of contraceptives      
(P= 0.26).  
To obtain more realistic correlation the duration of time of use should be considered rather than 
only used or not as the relation seem to be affected by the duration of use contraceptives [156-
158]. 
In addition, using oral contraceptives may increase breast cancer risk. However, the opposite was 
demonstrated in many epidemiologic studies in which no association between the use of oral 
contraceptive and the risk of breast cancer was shown. Recently, however, a large meta-analysis 
calculated a small but significant increase in relative risk of breast cancer (RR = 1.24) in current 
oral contraceptive users [97].  
5.7 Breast cancer correlation with number of pregnancies 
In our study there was no association between breast cancer incidence and number of 
pregnancies. Mutated and non- mutated in BRCA1/2 genes, showed  no statistical significant 
relationship (P=1.0) However this association has been observed in other population. An 
increased number of births were associated with a decreased risk of breast cancer in BRCA2-
negative cases but not in BRCA2-positive cases. An increasing age at menarche, a low age at first 
birth, an increasing parity and breast feeding are associated with a reduced risk of breast cancer in 
the general population [92 – 95].  
5.8 Breast cancer correlation with onset of disease 
In our study there was statistical significant relationship of breast cancer patients related to 
women age of onset of disease (P= 0.00), hazard ratio (OR) = 4.1 [95%CI= 1.73-9.77]. The study 





5.9 Breast cancer correlation with common genetic mutations 
 Among 122 women with sporadic and hereditary breast cancer, there were 24 patients had 
BRCA1 (49%), 13 patients had BRCA2 (26.5%) and 12 patients had both mutations (24.5%). The 
number of the patients with mutations were 49 patients ( 52.1%) and the rest 45 patients (47.9%) 
were normal (wt). BRCA1 and BRCA2 mutation is an established component of risk evaluation 
and management of familial breast cancer. Carriers of germ line mutations in these  two genes are 
























Conclusions and recommendations 
 
6.1 Conclusions 
 The risk of breast cancer increased with the age, age at first birth, age of 
onset of disease. 
 There was no influence risk of breast cancer with the factors; age at 
menarche, breast feeding, no. of pregnancies, using oral contraceptives, and 
the presence of relatives with breast cancer. 
 The incidence of BRCA1 mutations (185AG and 5382C mutations)  was 
more than BRCA2 mutation ( 6174T mutation).  
6.2 Recommendations 
 This study has highlighted the need of a breast cancer awareness campaign, which should 
also stress the importance of early detection and reporting of breast cancer. 
 Extensive mutation screening of high-risk breast cancer primarily targeting early-onset 
cases should be undertaken in Gaza Strip with proper genetic counseling, since female 
carriers of mutations in these genes are also at a high risk for developing a second 
malignancy either in the breast or ovary.  
 Personal risk information may help in taking preventive measures and also motivate a 
high-risk woman to adopt breast screening that may promote early detection and improve 
chances of surviving breast cancer.  
 Women found to carry a pathogenic variant can be advised to undergo regular screening 
by mammography or magnetic resonance imaging and to consider risk-reducing surgery. 
In addition, their relatives who do not carry the pathogenic variant can be able to seek 
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Questionnaire                                                                                                      
  .میسرة سلیم صالح: أختكم الباحثة 
و  ي العل ستیر ف ة ماج المیة طالب ة اإلس ي الجامع ة ف ستیر م الحیاتی الة  الماج ن رس ائي م ث النھ وم بالبح وأق
  .والتي تدرس الطفرات الوراثیة المسببة لمرض سرطان الثدي في قطاع غزة 
ة وھو فحص جیني غیر متوفر في ق  ة االستبیان و اإلجاب ي تعبئ ذا أرجو من سیادتكن المساعدة ف طاع غزة ل
  .على األسئلة بصدق لیعطي الغایة المرجوة منھ
  .علمًا بأن المعلومات الواردة في االستبیان سریة جدًا و خاصة للبحث العلمي فقط
  . للمرضكما وأرجو الموافقة على سحب عینة دم لعمل الفحص الجیني عن الطفرات المسببة
  
  
  التوقیع  االسم  م
١ .       
٢ .       
٣ .       
٤ .       
٥ .       
٦ .       
٧ .       
٨ .       
٩ .       
١٠ .     
١١ .     
١٢ .     
١٣ .     
١٤ .     
١٥ .     
١٦ .     
١٧ .     
١٨ .     
١٩ .     
٢٠ .     
٢١ .     
٢٢ .     
٢٣ .     
٢٤ .     







● Name: -----------------------------------------------------     ● Birth date:        /        /         
● Age:  ------------------ Years. 
● Length:-------------- cm             ● Weight:  ---------- kgs                ● Obesity: □ Yes  □  No 
      ●Address:----------------------------------------------------------------------------------------------------
----------------------------------------------------------------------------------------------------- 
●  The age at the first ministration (menarche): ------------------------------------------- 
●The age at marriage:  ------------------------------------------------------------------------------              
 ●   Parents  consanguinity: --------------------------------------------------------- 
        ●The age at first birth:   -----------------------------------------------------------------                    
   ●No. of pregnancies: ---------------------                
     ●No. of siblings:   ------------------------          
●The time of breast feeding:   - -- - -- - -- - -- - -- -- - -- - -- - -- - -- - -- -- - -- - -- - - -- -- - -- - -- - -- - -- - -- -- --  
  ●Using contraceptives: ----------------------------------------------------------------------- 
  ●Duration of use: ------------------------------------------------------------------------------------  
  ●Onset of the disease:   ---------------------------------------------------------------------------- 
 Any treatment or hormones medicine:--------------------------------------------------------------  







  .......................................................................................... : االسم-١
  ..................... ....................:م     العمر     /          /           : تاریخ المیالد -٢
      ......................................... ............................................:  الطول -٣
  ...................................................................................:    الوزن -٤
  ............................................................  ........................: العنوان-٥
.........................................................................................................  
  ..................................................................:  العمر عند أول دورة شھریة -٦
  ..............................................................................:  العمر عند الزواج -٧
  .............................. ..........................................: العمر عند أول والدة -٨
  ......................................... ............................: عدد مرات الحمل -٩
  ....................-٣ ............-٢...................-١ :مل  فترة الرضاعة في كل ح-١٠
٨.................-٧.................-٦................-٥..................-٤-.................  
    ال □ نعم                      □ :     ھل تناولت حبوب منع الحمل-١١
  . أقل من ذلك □أكثر □  سنتان  □سنة ونصف□  سنة□ شھور٦□  :فترة االستخدام  -١٢
  ........................................... ...........:المرض ) اكتشاف ( تاریخ بدایة -١٣
    ال □                             نعم  □  : ھل تناولت أدویة لعالج الھرمون -١٤
   ال □                           نعم    □              : ھل األب واألم أقارب -١٥
    ال □                             نعم □:    ھل یوجد أفراد في عائلتك مصابین بالمرض-١٦
  ............................................:  األفراد المصابین بالمرض من العائلة -١٧
  













 Figures of the experimental technology of the materials and methods of the study 
Figure 5.1; The streptavidin coated 96-well ELISA plate. 
 
 








Figure 5.3; The pronto kit.                                            Figure 5.4;The thermocycler (PCR).      








Figure 5.5; Primer extension reaction using a multichannel pipette. 
 
  
  
